KyleColvettMD

Radiation Oncology • Johnson City, TN

Medical Director

Join to view full profile

Dr. Colvett is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Colvett's full profile

Already have an account?

Office
400 N State Of Franklin Rd
Cancer Treatment Center
Johnson City, TN 37604
Phone+1 423-431-6000

Fax+1 423-431-6060

Summary

Busy private practice radiation oncologist with teaching appointments and clinical trial emphasis.

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology, 1993 - 1996
East Tennessee State University/Quillen College of MedicineInternship, Surgery, 1992 - 1993
East Tennessee State University James H. Quillen College of MedicineClass of 1992

Certifications & Licensure

TN State Medical License 1996 - 2026
American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

Service Award American Board of Radiology, 2022
Reader’s Choice Awards—Favorite Cancer Doctor Johnson City Press, 2016-2017, 2019-2021
Highest Patient Satisfaction Score in Region Press Ganey, 2014-2015, 2017
America’s Top Docs Castle Connolly, 2008-2009, 2011, 2017
Healthcare Heroes TriCities Health, 2005, 2009
Servant’s Heart Milligan University, 2006
James Gibson Award Medical Staff Leadership Johnson City Medical Center— Ballad Health, 2005
Forty Under Forty The Business Journal, 2002
Join now to see all

Clinical Trials

Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers Start of enrollment: 2018 Jul 12
Completed
Phase 2
ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients Start of enrollment: 2018 Oct 03
Completed
Phase 3
Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer. Start of enrollment: 2021 Feb 11
Terminated
Phase 2, Phase 3
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867) Start of enrollment: 2019 Jun 25
Active, not recruiting
Phase 3
Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases Start of enrollment: 2002 Mar 01
Completed
Phase 3
A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942) Start of enrollment: 1996 Mar 01
Completed
Phase 2
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer Start of enrollment: 2005 Mar 01
Completed
Not Applicable
MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ Start of enrollment: 2003 Aug 01
Completed
Phase 2
Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma Start of enrollment: 2013 Jul 01
Active, not recruiting
Early Phase 1
Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall Start of enrollment: 2004 Jun 17
Terminated
Phase 2
Axillary Lymph Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node Start of enrollment: 2013 Jan 01
Withdrawn
Phase 3
Axillary Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node Start of enrollment: 2012 Jul 19
Active, not recruiting
Not Applicable
Join now to see all

Publications & Presentations

PubMed

11 citations
PREVLAR: Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Head and Neck Chemoradiother...
Marcelo Bonomi, Dukagjin M Blakaj, Rafi Kabarriti, Kyle Colvett, Vinita Takiar
International Journal of Radiation Oncology, Biology, Physics. 2023-07-01
60 citations
Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer.
Carryn M. Anderson, Christopher M. Lee, Deborah P. Saunders, Amarinthia Curtis, Neal Dunlap
Journal of Clinical Oncology. 2019-10-16
20 citations
Radiation-related arterial disease
Tony Katras, Ulises Baltazar, Kyle T. Colvett, Daniel S. Rush, Julie Dunn
The American Surgeon. 1999-12-01

Journal Articles

Opportunities with combined modality therapy for selective organ preservation in muscle-invasive bladder cancer
Kyle T. Colvett MD, Alex F. Althausen MD, Barbara Bassil MD, Niall M. Heney MD, Francis V. McGovern MD, Hugh H. Young II MD, Donald S. Kaufman MD, Journal of Surgical Oncology, 11/1996

Committees

Chief of Staff, Executive Committee 1999 - 2001

Professional Memberships

Alpha Omega Alpha Honor Medical Society - AOA
Member
American College of Radiology - ACR
Member
American Roentgen Ray Society - ARRS
Member
American Society for Radiation Oncology - ASTRO
Member
American College of Physician Executives - ACPE
Member
Royal Society of Medicine
Member
Association of Military Surgeons of the United States
Member
American Association for Cancer Research - AACR
Member
American Brachytherapy Society
Member
American College of Radiation Oncology
Member
American Society of Clinical Oncology - ASCO
Member

KyleColvettMD

Dr. Colvett is on Doximity

Summary

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Committees

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.